B细胞成熟抗原靶向治疗在AL淀粉样变性中的更新
系统性轻链(AL)淀粉样变性是一种罕见的克隆性浆细胞疾病,标准一线治疗为达雷妥尤单抗、环磷酰胺、硼替佐米和地塞米松联合方案(D-VCd方案),但疾病仍不可治愈且所有患者终将复发。B细胞成熟抗原(BCMA)在AL淀粉样变性浆细胞上也有表达,尽管低于多发性骨髓瘤(MM),本综述旨在提供抗BCMA治疗在AL淀粉样变性中的疗效与毒性的最新信息。
要点
- AL淀粉样变性标准一线治疗为D-VCd方案,可获得高比例的血液学和器官缓解。
- BCMA在AL淀粉样变性浆细胞上表达,但表达水平低于多发性骨髓瘤。
- 多种抗BCMA免疫疗法已获批用于复发/难治性多发性骨髓瘤,包括belantamab mafodotin、teclistamab、elranatamab、idecabtagene vicleucel和ciltacabtagene autoleucel。
核心结论
- AL淀粉样变性仍不可治愈,所有患者终将复发,对缓解不充分或复发/难治患者需要新的治疗选择。
- BCMA是AL淀粉样变性的一个有前景的治疗靶点,尽管其表达低于多发性骨髓瘤。
- 本综述旨在提供抗BCMA治疗在AL淀粉样变性中的疗效与毒性的最新信息。
研究设计与样本
- 本综述旨在提供抗BCMA治疗在AL淀粉样变性中的疗效与毒性的最新信息。
主要发现
- 标准一线治疗D-VCd方案可获得高比例的血液学和器官缓解。
- BCMA在多发性骨髓瘤和AL淀粉样变性的浆细胞上过表达,在AL淀粉样变性中的表达低于多发性骨髓瘤。
- 多种抗BCMA免疫疗法已获批用于复发/难治性多发性骨髓瘤,包括抗体药物偶联物belantamab mafodotin、双特异性抗体teclistamab和elranatamab以及嵌合抗原受体T细胞疗法idecabtagene vicleucel和ciltacabtagene autoleucel。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic light chain (AL) amyloidosis is a rare clonal plasma cell disorder characterized by the production of amyloidogenic immunoglobulin light chains, which causes the formation and deposition of amyloid fibrils, leading to multi-organ dysfunction. Current treatment is directed at the underlying plasma cell clone to achieve a profound reduction in the monoclonal free light chain production. The standard-of-care first-line therapy is a combination of daratumumab, cyclophosphamide, bortezomib and dexamethasone (D-VCd regimen), resulting in high rates of haematological and organ responses. However, AL amyloidosis remains incurable, and all patients inevitably relapse. Hence, novel treatment options are needed for patients with an inadequate response or relapsed/refractory disease. B-cell maturation antigen (BCMA) is a tumour necrosis factor (TNF receptor superfamily receptor overexpressed on plasma cells in multiple myeloma (MM) and AL amyloidosis. Recently, several novel anti-BCMA immunotherapies have been approved for the treatment of relapsed/refractory MM, including antibody-drug conjugate belantamab mafodotin, bispecific antibodies teclistamab and elranatamab and chimeric antigen receptor T-cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel. Despite lower expression than in MM, BCMA is also a promising target in AL amyloidosis. This review aims to provide up-to-date information on the efficacy and toxicity of anti-BCMA therapy in AL amyloidosis.
引用
- Jamroziak K, Zielonka K, Khwaja J, et al. Update on B-cell maturation antigen-directed therapies in AL amyloidosis. Br J Haematol. 2025. PMID: 39748220. doi:10.1111/bjh.19960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。